ASCO: Ramucirumab Plus Pembrolizumab Promising in NSCLC
Early research shows that overall survival is longer with ramucirumab and pembrolizumab compared with an investigator’s choice SOC in advanced NSCLC.
Early research shows that overall survival is longer with ramucirumab and pembrolizumab compared with an investigator’s choice SOC in advanced NSCLC.
Patients in the first arm will undergo single booster vaccination, and patients in the second arm will undergo full revaccination.
Medicaid beneficiaries had a higher risk of death than commercially-insured patients, but the risk of death decreased if Medicaid beneficiaries underwent biomarker testing.
For patients with SCLC with intracranial metastatic disease (IMD), outcomes appear to be no worse with SRS compared with WBRT.
Medicaid expansion under the ACA was associated with an increase in two-year overall survival among patients newly diagnosed with cancer.
The remote monitoring intervention reduced the rate of grade 3 or higher adverse events and the length of hospital stays.
Younger patients with cancer are “a high-risk population for poor outcomes from COVID-19,” according to researchers.
Immunotherapy prolonged survival compared with platinum chemotherapy.
Of more than 100 studies used to support drug approvals, none reported information on the gender of participants.
Having a high blood tumor mutational burden was associated with a significant improvement in response and a trend toward improvement in survival outcomes.